Advancing science and implementing novel, cutting edge Technologies

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

 

Global Research and early development
Chemin des mines, 9
CH1202, Geneva, Switzerland

 

merckserono.com

 

Project leader

 
Dr. Paul Lang
Associate director
Phone +41 22 414 98 69
Fax +41 22 414 95 580
E-Mail  

Institute presentation

Merck Serono is the biopharmaceutical division of Merck KGaA. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurodegenerative diseases, oncology and rheumatology

 

 

Binger Straße 173

D-55216 Ingelheim

Germany

 

boehringer-ingelheim.de

 

Project leader

 
Dr. Ralf Heilker
Lead Identification
Phone +49 7351 54 5590
Fax +49 7351 83 5590
E-Mail  


Co-Project leader

 
Dr. Mario Beilmann
Nonclinical Drug Safety
88397 Biberach an der Riss
Phone +49 7351 547726
Fax +49 7351 54 98686
E-Mail  

 

Project staff

 
Prof. Bastian Hengerer
CNS Diseases Research
Phone +49 7351 54 4742
Fax +49 7351 83 4742
E-Mail  

 

 
Prof. Frank Gillardon
CNS Diseases Research
Phone +49 7351 54 8460
Fax +49 7351 83 8460
E-Mail  

 

 
Dr. Tobias Hildebrandt
Target Discovery Research
Phone +49 7351 54 547819
Fax +49 7351 54 547819
E-Mail  

 

 
Dr. Florian Meier
Toxicology & Assay development
Phone +49 7351 54 143219
   
E-Mail  

 

 
Dr. Rolf Göggel

Research Networking
88397 Biberach an der Riss

Germany

Phone +49 7351 54 96889
Fax +49 7351 54 5997
E-Mail  

 


Institute presentation

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with high unmet medical need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on six major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Infectious diseases, Oncology and Respiratory diseases.

boehringer-ingelheim.com

 
Division of Biotechnology/IFM
581 823 Linköping, Sweden

 

ifm.liu.se

 

Project leader

 
Prof. Carl-Fredrik Mandenius
 
Phone +46 13 288967
E-Mail  

Project staff

 
Jonas Christoffersson, Res.eng.
 
E-Mail  

 


Institute presentation

LiU is a leading Swedish university located in Linköping and Norrköping with strong focus on sensor and measurement technology.  Its institute of IFM has international groups in sensor technology (Turner) and biotechnology (Mandenius). The university has two science park establishments. The university has a strong focus on engineering and education. See also www.liu.se

 

 

Bioengineering Department

Royallieu Research Center, BP 20529

60205 Compiegne Cedex, France.

 

utc.fr

 

Project leader

 
Elias Zgheib
 
E-Mail  

Institute presentation

UTC is a public institution specialized in science and technology.  It was created in 1972 as a new model in the French higher education system. This experiment aimed at bridging the gap between :

  • the elite school system (Grandes Ecoles) and the standard universities
  • the higher education institutions and industry

UTC’s main missions are education, research and transfer of technology.  It is well integrated within the European system of higher education and it has pursued, since its creation, an ambitious international policy.

UTC interacts with society and industry by anticipating the research's requirements of companies and by facilitating the professional insertion of its students, thanks to its educational values based on students' autonomy and its interdisciplinary research.

The UTC Chair of Mathematical Modelling for Systems Toxicology develops multidisciplinary research projects and teaching in at the interface between bioinformatics, biostatistics, mathematics and pharmacology or toxicology.  Our core expertise is Bayesian statistics, data integration, physiologically based pharmacokinetic modeling and systems biology models of metabolic regulations.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline